Estrogen replacement therapy (ERT) - [Medication] - Quest Diagnostics Patient Health Library Topic Contents - Examples - How It Works - Why It Is Used - How Well It Works - Side Effects - What To Think About - References Estrogen replacement therapy (ERT) - [Medication] - Quest Diagnostics Patient Health Library Estrogen replacement therapy (ERT) - [Medication] - Quest Diagnostics Patient Health Library Hormones, Sexual and reproductive organs, Sexual health, Women’s...
BioPortfolio Limited focus of concern shifts towards the UK 70 Market analysis: leading and new product sales to 2008 71 Wyeth 73 Premarin family (conjugated estrogens) 73 Novartis 79 Schering AG 79 Climara and Climara Pro (estradiol) 80 Avaden (estradiol/gestodene) 81 Solvay 82 Estratest (esterified estrogens/methyltestosterone) 82 Organon 83 Novo Nordisk 84 Outlook for the HRT market...
What's new at CDER by Date New and Generic Drug Approvals Desogestrel & Ethinyl Estradiol Tablets, Barr Laboratories Methamphetamine Hydrochloride Tablets, Able Laboratories Mexitil (mexiletine hydrochloride) Capsules, Boehringer Ingelheim Pediatric Drug Development: Pediatric Exclusivity Granted (updated) Federal Register Notice (69 FR 7243)- List of Drugs for Which Pediatric Studies Are Needed --...
author: Paul Stauffer
Estrogen and Estrogen with Progestin Therapies for Postmenopausal Women FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Estrogen and Estrogen with Progestin-Therapies for-Postmenopausal Women The Food and Drug Administration has received requests from the public to provide updated product information for estrogen- and progestin-containing drug products used for treating postmenopausal symptoms
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf The ~an steady state levels (Cavg) of the estradiol during the application of Climara 8 25 cm2 and 12.5 Cm2 on the ~ were about 80 and 40 Pg/ mLClimara~ has been conducted in a pediabic population, Gender: Climara8 is indicated for use in wo~ n only, Race: No studies were done to detemrlne the effect of race on the...
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 22
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 21
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 20
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 7
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 6
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 5
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 2
author: QUANG [ CDW5101588 ]
http://www.fda.gov/cder/foi/label/2004/020375S020lbl.pdf page 1
author: QUANG [ CDW5101588 ]
1996 and Older - New Drug Application (NDA) New Drug Approval Packages These drug approval packages, sorted by product trade name, are supplied by the CDER Freedom of Electronic Information Office
Paragraph IV Patent Certifications - DRUG NAME DOSAGE FORM STRENGTH RLD Acetaminophen Extended-release Tablets 650 mg Tylenol Acetaminophen/ Aspirin/ Caffeine Tablets 250 mg/250 mg/ 65 mg Excedrin (migraine) Acetaminophen and Tramadol Hydrochloride Tablets 325 mg/ 37.5 mg Ultracet Acyclovir Sodium1 Injection 50 mg/mL, 10 mL and 20 mL vials Zovirax Albuterol Sulfate Oral Syrup 2 mg(base)/ 5 mL Ventolin Albuterol...
C:\Data\My Documents\drugs\estrogen\WHI labeling supps\Climara\AP\ letter S-020.doc page 1
author: Bronwyn Collier
http://www.fda.gov/cder/orange/appendix_a.txt 3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE #3, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN W/ CODEINE, ACETAMINOPHEN ACETAMINOPHEN, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC) ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, ACETAMINOPHEN ACETAMINOPHEN, BUTALBITAL AND CAFFEINE, ACETAMINOPHEN ACETAMINOPHEN,...
1997 Warning Letters and Notice of Violation Letters to Pharmaceutical Companies DDMAC 3/4/1997 Claritin-D 24 Hour (10 mg loratadine & pseudoepherine 240 mg sulfate) extended-release tablets Schering Corporation DDMAC 3/26/1997 Climara (estradiol transdermal system) Forest Laboratories DDMAC 3/26/97 Famvir (famciclovir) SmithKline Beecham Pharmaceuticals DDMAC 3/11/1997 Gemzar (gemcitabine HCl) Eli Lilly and Company DDMAC 3/19/1997 Hycamtin (topotecan...
1998 Warning Letters and Untitled Letters to Pharmaceutical Companies DDMAC 6/25 6/29 Maxipime (Cefepime HCl) for Injection Bristol-Myers Squibb DDMAC 6/29 8/3 Mircette (Desogestrel/Ethinyl Estradiol and Ethinyl Estradiol) Tablets Organon DDMAC 6/1 6/9 Naprelan (Naproxen Sodium) Tablets Wyeth-Ayerst DDMAC 6/8 6/29 Nasacort (Triamcinolone Acetonide) Rhone-Poulenc Rorer DDMAC 6/25 6/29 Nasonex (mometasone furoate monohydrate) nasal spray...
2003 Warning Letters and Untitled Letters to Pharmaceutical Companies DDMAC 7/29/2003 8/7/2003 Yasmin (drospirenone/ethinyl estradiol) tablets Berlex Laboratories DDMAC 7/10/2003 7/15/2003 June 2003 Product Company Division Released Posted Amnesteem (isotretinoin) capsules King and Spaulding DDMAC 6/18/2003 6/19/2003 Drug Importation - Warning Letter CanadianDiscountDrugs Compliance 6/30/2003 11/6/2003 Flonase (fluticasone propionate) nasal spray...
author: STAUFFERP
NDA Approvals for Calendar Year 2003 NDA APPROVALS FOR CALENDAR YEAR 2003 Updated through December 31, 2003 NDA NUMBER DRUG NAME GENERIC NAME APPLICANT/ SPONSOR CHEMICAL TYPE THERAPEUTIC CLASS APPROVAL DATE - 21434 Xanax XR Alprazolam Pharmacia and Upjohn FR 3 S 17-Jan-03 21305 Sodium Iodide I-131 Sodium Iodide I-131 DraxImage 3,5 S 24-Jan-03 20414 Pyridostigmine Bromide Pyridostigmine Bromide US Army 3 P 05-Feb-03...
author: Susan Daugherty
Pharmaceutical Research and Manufacturers of America - Osteoporosis Complete a new search Drug Name (Proprietary name/Generic name) Indications Addressed Click on indication to see all drugs for that indication Company Click a company to see all drugs for that company Development Status Notes 3339 SERM none / 3339 SERM Osteoporosis Aventis Pharmaceuticals Bridgewater, NJ Phase II - bazedoxifene none / bazedoxifene Osteoporosis Ligand...
Prescription and Over-the-Counter Drug Product List: 11/2003 ACTHAR GEL >D> BC + QUESTCOR PHARMS 80 UNITS/ML N08372 008 NOV CTEC >A> + 80 UNITS/ML N08372 008 NOV CTEC CYTARABINE INJECTABLE; INJECTION >D> CYTARABINE >D> AP + GENSIA SICOR PHARMS 100MG/VIAL N16793 001 NOV DISC >D> AP + 500MG/VIAL N16793 002 NOV DISC >D> AP + 1GM/VIAL N16793 003 DEC 21, 1987 NOV DISC >D> AP + 2GM/VIAL N16793 004 DEC 21, 1987 NOV DISC >A> @ SICOR PHARMS 100MG/VIAL...
NDA-I1: NDA Approval Letter page 1
author: CDER User
subject: NDA Approval Letter - Approval letter based on enclosed/submitted labeli\ ng text
Press Release-Patient Education for those with MS - About Berlex | Contact Us | Feedback | Site Map | Search - Patients Healthcare Professionals Clinical Trials Pressroom FDA APPROVES TWO NEW DOSES OF CLIMARA TRANSDERMAL ESTROGEN THERAPY New Doses Now Available in Pharmacies Will Allow For More Individualized Treatment of Menopause Symptoms and Osteoporosis Prevention Montville, NJ [July 29, 2003] Berlex Laboratories, Inc.,...
